236 related articles for article (PubMed ID: 36919100)
1. PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise.
Bou Zeid N; Yazbeck V
Blood Lymphat Cancer; 2023; 13():1-12. PubMed ID: 36919100
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
3. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
Pongas G; Cheson BD
Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
[TBL] [Abstract][Full Text] [Related]
4. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
5. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives.
Hus I; Puła B; Robak T
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326722
[TBL] [Abstract][Full Text] [Related]
8. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
Maharaj K; Powers JJ; Achille A; Mediavilla-Varela M; Gamal W; Burger KL; Fonseca R; Jiang K; Miskin HP; Maryanski D; Monastyrskyi A; Duckett DR; Roush WR; Cleveland JL; Sahakian E; Pinilla-Ibarz J
Blood Adv; 2020 Jul; 4(13):3072-3084. PubMed ID: 32634240
[TBL] [Abstract][Full Text] [Related]
9. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
[TBL] [Abstract][Full Text] [Related]
10. Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib.
Shah A; Barrientos JC
Onco Targets Ther; 2021; 14():2109-2119. PubMed ID: 33790574
[TBL] [Abstract][Full Text] [Related]
11. The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma.
Schweitzer J; Hoffman M; Graf SA
Expert Opin Pharmacother; 2022 Apr; 23(5):535-541. PubMed ID: 35209784
[TBL] [Abstract][Full Text] [Related]
12. Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia.
Visentin A; Frezzato F; Severin F; Imbergamo S; Pravato S; Romano Gargarella L; Manni S; Pizzo S; Ruggieri E; Facco M; Brunati AM; Semenzato G; Piazza F; Trentin L
Onco Targets Ther; 2020; 13():9679-9688. PubMed ID: 33061448
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
14. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Fowler NH; Samaniego F; Jurczak W; Ghosh N; Derenzini E; Reeves JA; Knopińska-Posłuszny W; Cheah CY; Phillips T; Lech-Maranda E; Cheson BD; Caimi PF; Grosicki S; Leslie LA; Chavez JC; Fonseca G; Babu S; Hodson DJ; Shao SH; Burke JM; Sharman JP; Law JY; Pagel JM; Miskin HP; Sportelli P; O'Connor OA; Weiss MS; Zinzani PL
J Clin Oncol; 2021 May; 39(15):1609-1618. PubMed ID: 33683917
[TBL] [Abstract][Full Text] [Related]
15. Current status of phosphoinotiside-3 kinase inhibitors in blood cancers.
Shouse G; Danilova OV; Danilov AV
Curr Opin Oncol; 2022 Sep; 34(5):540-545. PubMed ID: 35855508
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.
Mensah FA; Blaize JP; Bryan LJ
Onco Targets Ther; 2018; 11():4817-4827. PubMed ID: 30147333
[TBL] [Abstract][Full Text] [Related]
17. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.
Flinn IW; O'Brien S; Kahl B; Patel M; Oki Y; Foss FF; Porcu P; Jones J; Burger JA; Jain N; Kelly VM; Allen K; Douglas M; Sweeney J; Kelly P; Horwitz S
Blood; 2018 Feb; 131(8):877-887. PubMed ID: 29191916
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
20. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
